References
Items 685 to 696 of 6390 total
- Robbins JD et al. (JUL 1996) Journal of medicinal chemistry 39 14 2745--52
Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.
Three series of analogs were regioselectively prepared from a protected forskolin precursor to afford 7-carbamoyl-7-desacetylforskolins (series 1), 6-carbamoyl-7-desacetylforskolins (series 2), and 6-carbamoylforskolins (series 3). The analogs were pharmacologically evaluated for binding (IC50) to and activation (EC50) of type I adenylyl cyclase in membranes from stably transfected Sf9 cell lines expressing a single adenylate cyclase subtype. The following ranges were determined for the IC50's and EC50's of each individual series: series 1, IC50 = 43-1600 nM, EC50 = 0.5-9.6 microM; series 2, IC50 = 65-680 nM, EC50 = 0.63-6.5 microM; series 3, IC50 = 21-271 nM, EC50 = 0.5-8.1 microM (forskolin IC50 = 41 nM and EC50 = 0.5 microM). Activation paralleled binding; however, some analogs exhibited poor binding and good activation whereas others demonstrated good binding but poor activation. Steric bulk tended to diminish binding and activation when at the 6- or 7-position, although bulk was accommodated at the 6-position if the 7-site was reacetylated. Acylation of the 7-position by the carbamoyl linker or acetyl was important for obtaining good binding and activation; however, the effect was more pronounced with binding. For both binding and activation, small, linear, lipophilic substituents (propyl, allyl, isopropyl) are well tolerated at the 7-position but less so in the 6-position, even when the 7-site is reacetylated. Planar aromatic moieties (phenyl and 2-pyridinyl) demonstrated moderate to good potency for binding and activation when located at either the 6- or 7-positions. There is an overall trend toward increasing potency for both binding and activation with polar substituents.Catalog #: Product Name: 72112 Forskolin Catalog #: 72112 Product Name: Forskolin Minucci S et al. (MAR 1996) Proceedings of the National Academy of Sciences of the United States of America 93 5 1803--7Retinoid X receptor-selective ligands produce malformations in Xenopus embryos.
Retinoids exert pleiotropic effects on the development of vertebrates through the action of retinoic acid receptors (RAR) and retinoid X receptors (RXR). We have investigated the effect of synthetic retinoids selective for RXR and RAR on the development of Xenopus and zebrafish embryos. In Xenopus, both ligands selective for RAR and RXR caused striking malformations along the anterior-posterior axis, whereas in zebrafish only ligands specific for RAR caused embryonic malformations. In Xenopus, RAR- and RXR-selective ligands regulated the expression of the Xlim-1, gsc, and HoxA1 genes similarly as all-trans-retinoic acid. Nevertheless, RXR-selective ligands activated only an RXR responsive reporter but not an RAR responsive reporter introduced by microinjection into the Xenopus embryo, consistent with our failure to detect conversion of an RXR-selective ligand to different derivatives in the embryo. These results suggest that Xenopus embryos possess a unique response pathway in which liganded RXR can control gene expression. Our observations further illustrate the divergence in retinoid responsiveness between different vertebrate species.Catalog #: Product Name: 72892 TTNPB Catalog #: 72892 Product Name: TTNPB Jones RJ et al. (JUL 1996) Blood 88 2 487--91Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity.
The classical definition of lymphohematopoietic stem cells (LHSC), the most primitive progenitors of all blood cells, requires that they have the capacity for self-renewal and for the long-term production of all blood cell lineages. However, other characteristics of LHSC have been debated. Our previous data suggested that mouse LHSC are very slowly proliferating cells that generate delayed multilineage engraftment, while radioprotection" (rapid engraftment that will prevent early death from radiation-induced marrow aplasia) results from more committed progenitors. Alternatively�Catalog #: Product Name: 01701 ALDEFLUOR™ Assay Buffer 01700 ALDEFLUOR™ Kit 01705 ALDEFLUOR™ DEAB Reagent Catalog #: 01701 Product Name: ALDEFLUOR™ Assay Buffer Catalog #: 01700 Product Name: ALDEFLUOR™ Kit Catalog #: 01705 Product Name: ALDEFLUOR™ DEAB Reagent J. A. Kennedy et al. (jul 1996) Biochemical pharmacology 52 2 273--80Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone.
The mechanism of the anti-anginal effect of perhexiline is unclear but appears to involve a shift in cardiac metabolism from utilization of fatty acid to that of carbohydrate. We tested the hypothesis that perhexiline inhibits the enzyme carnitine palmitoyltransferase-1 (CPT-1), which controls access of long chain fatty acids to the mitochondrial site of beta-oxidation. Perhexiline produced a concentration-dependent inhibition of CPT-1 in rat cardiac and hepatic mitochondria in vitro, with half-maximal inhibition (IC50) at 77 and 148 mumol/L, respectively. Amiodarone, another drug with anti-anginal properties, also inhibited cardiac CPT-1 (IC50 = 228 mumol/L). The rank order of potency for inhibition was malonyl-CoA {\textgreater} 4-hydroxyphenylglyoxylate (HPG) = perhexiline {\textgreater} amiodarone = monohydroxy-perhexiline. Kinetic analysis revealed competitive inhibition of cardiac and hepatic CPT-1 by perhexiline with respect to palmitoyl-CoA but non-competitive inhibition with respect to carnitine. Curvilinear Dixon plots generated apparent inhibitory constant (Ki)" values for perhexiline which indicated a greater sensitivity of the cardiac than the hepatic enzyme to inhibition by perhexiline. Perhexiline inhibition of CPT-1 unlike that of malonyl-CoA and HPG was unaffected by pretreatment with the protease nagarse. These data establish for the first time that two agents with proven anti-anginal effects inhibit cardiac CPT-1. This action is likely to contribute to the anti-ischaemic effects of both perhexiline and amiodarone."Catalog #: Product Name: 100-0267 Perhexiline Maleate Catalog #: 100-0267 Product Name: Perhexiline Maleate Petzer AL et al. (JUN 1996) The Journal of experimental medicine 183 6 2551--8Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.
A high proportion of the CD34+CD38- cells in normal human marrow are defined as long-term culture-initiating cells (LTC-IC) because they can proliferate and differentiate when co-cultured with cytokine-producing stromal feeder layers. In contrast, very few CD34+CD38- cells will divide in cytokine-containing methylcellulose and thus are not classifiable as direct colony-forming cells (CFC), although most can proliferate in serum-free liquid cultures containing certain soluble cytokines. Analysis of the effects of 16 cytokines on CD34+CD38- cells in the latter type of culture showed that Flt3-ligand (FL), Steel factor (SF), and interleukin (IL)-3 were both necessary and sufficient to obtain an approximately 30-fold amplification of the input LTC-IC population within 10 d. As single factors, only FL and thrombopoietin (TPO) stimulated a net increase in LTC-IC within 10 d. Interestingly, a significantly increased proportion of the CFC produced from the TPO-amplified LTC-IC were erythroid. Increases in the number of directly detectable CFC of textgreater 500-fold were also obtainable within 10 d in serum-free cultures of CD34+CD38- cells. However, this required the presence of IL-6 and/or granulocyte/colony-stimulating factor and/or nerve growth factor beta in addition to FL, SF, and IL-3. Also, for this response, the most potent single-acting factor tested was IL-3, not FL. Identification of cytokine combinations that differentially stimulate primitive human hematopoietic cell self-renewal and lineage determination should facilitate analysis of the intracellular pathways that regulate these decisions as well as the development of improved ex vivo expansion and gene transfer protocols. View PublicationCatalog #: Product Name: 05100 MyeloCult™ H5100 09300 10% Bovine Serum Albumin in Iscove's MDM 09500 BIT 9500 Serum Substitute Catalog #: 05100 Product Name: MyeloCult™ H5100 Catalog #: 09300 Product Name: 10% Bovine Serum Albumin in Iscove's MDM Catalog #: 09500 Product Name: BIT 9500 Serum Substitute Jiang Y et al. (JUL 1996) The Journal of biological chemistry 271 30 17920--6Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta).
Mitogen-activated protein (MAP) kinase cascades represent one of the major signal systems used by eukaryotic cells to transduce extracellular signals into cellular responses. Four MAP kinase subgroups have been identified in humans: ERK, JNK (SAPK), ERK5 (BMK), and p38. Here we characterize a new MAP kinase, p38beta. p38beta is a 372-amino acid protein most closely related to p38. It contains a TGY dual phosphorylation site, which is required for its kinase activity. Like p38, p38beta is activated by proinflammatory cytokines and environmental stress. A comparison of events associated with the activation of p38beta and p38 revealed differences, most notably in the preferred activation of p38beta by MAP kinase kinase 6 (MKK6), whereas p38 was activated nearly equally by MKK3, MKK4, and MKK6. Moreover, in vitro and in vivo experiments showed a strong substrate preference by p38beta for activating transcription factor 2 (ATF2). Enhancement of ATF2-dependent gene expression by p38beta was approximately20-fold greater than that of p38 and other MAP kinases tested. The data reported here suggest that while closely related, p38beta and p38 may be regulated by differing mechanisms and may exert their actions on separate downstream targets.Catalog #: Product Name: 72632 SB202190 Catalog #: 72632 Product Name: SB202190 Wymann MP et al. ( 1996) Molecular and cellular biology 16 4 1722--1733Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.
Wortmannin at nanomolar concentrations is a potent and specific inhibitor of phosphoinositide (PI) 3-kinase and has been used extensively to demonstrate the role of this enzyme in diverse signal transduction processes. At higher concentrations, wortmannin inhibits the ataxia telangiectasia gene (ATM)-related DNA-dependent protein kinase (DNA-PKcs). We report here the identification of the site of interaction of wortmannin on the catalytic subunit of PI 3-kinase, p110alpha. At physiological pH (6.5 to 8) wortmannin reacted specifically with p110alpha. Phosphatidylinositol-4,5-diphosphate, ATP, and ATP analogs [adenine and 5'-(4-fluorosulfonylbenzoyl)adenine] competed effectively with wortmannin, while substances containing nucleophilic amino acid side chain functions had no effect at the same concentrations. This suggests that the wortmannin target site is localized in proximity to the substrate-binding site and that residues involved in wortmannin binding have an increased nucleophilicity because of their protein environment. Proteolytic fragments of wortmannin-treated, recombinant p110alpha were mapped with anti-wortmannin and anti-p110alpha peptide antibodies, thus limiting the target site within a 10-kDa fragment, colocalizing with the ATP-binding site. Site-directed mutagenesis of all candidate residues within this region showed that only the conservative Lys-802-to-Arg mutation abolished wortmannin binding. Inhibition of PI 3-kinase occurs, therefore, by the formation of an enamine following the attack of Lys-802 on the furan ring (at C-20) of wortmannin. The Lys-802-to-Arg mutant was also unable to bind FSBA and was catalytically inactive in lipid and protein kinase assays, indicating a crucial role for Lys-802 in the phosphotransfer reaction. In contrast, an Arg-916-to-Pro mutation abolished the catalytic activity whereas covalent wortmannin binding remained intact. Our results provide the basis for the design of novel and specific inhibitors of an enzyme family, including PI kinases and ATM-related genes, that play a central role in many physiological processes. View PublicationCatalog #: Product Name: 73562 Wortmannin Catalog #: 73562 Product Name: Wortmannin Damen JE et al. (FEB 1996) Proceedings of the National Academy of Sciences of the United States of America 93 4 1689--93The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase.
A 145-kDa tyrosine-phosphorylated protein that becomes associated with Shc in response to multiple cytokines has been purified from the murine hemopoietic cell line B6SUtA1. Amino acid sequence data were used to clone the cDNA encoding this protein from a B6SUtA1 library. The predicted amino acid sequence encodes a unique protein containing an N-terminal src homology 2 domain, two consensus sequences that are targets for phosphotyrosine binding domains, a proline-rich region, and two motifs highly conserved among inositol polyphosphate 5-phosphatases. Cell lysates immunoprecipitated with antiserum to this protein exhibited both phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate polyphosphate 5-phosphatase activity. This novel signal transduction intermediate may serve to modulate both Ras and inositol signaling pathways. Based on its properties, we suggest the 145-kDa protein be called SHIP for SH2-containing inositol phosphatase.Petzer AL et al. (FEB 1996) Proceedings of the National Academy of Sciences of the United States of America 93 4 1470--4Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
A major goal of experimental and clinical hematology is the identification of mechanisms and conditions that support the expansion of transplantable hematopoietic stem cells. In normal marrow, such cells appear to be identical to (or represent a subset of) a population referred to as long-term-culture-initiating cells (LTC-ICs) so-named because of their ability to produce colony-forming cell (CFC) progeny for textgreater or = 5 weeks when cocultured with stromal fibroblasts. Some expansion of LTC-ICs in vitro has recently been described, but identification of the factors required and whether LTC-IC self-renewal divisions are involved have remained unresolved issues. To address these issues, we examined the maintenance and/or generation of LTC-ICs from single CD34+ CD38- cells cultured for variable periods under different culture conditions. Analysis of the progeny obtained from cultures containing a feeder layer of murine fibroblasts engineered to produce steel factor, interleukin (IL)-3, and granulocyte colony-stimulating factor showed that approximately 20% of the input LTC-ICs (representing approximately 2% of the original CD34+ CD38- cells) executed self-renewal divisions within a 6-week period. Incubation of the same CD34+ CD38- starting populations as single cells in a defined (serum free) liquid medium supplemented with Flt-3 ligand, steel factor, IL-3, IL-6, granulocyte colony-stimulating factor, and nerve growth factor resulted in the proliferation of initial cells to produce clones of from 4 to 1000 cells within 10 days, approximately 40% of which included textgreater or = 1 LTC-IC. In contrast, in similar cultures containing methylcellulose, input LTC-ICs appeared to persist but not divide. Overall the LTC-IC expansion in the liquid cultures was 30-fold in the first 10 days and 50-fold by the end of another 1-3 weeks. Documentation of human LTC-IC self-renewal in vitro and identification of defined conditions that permit their extensive and rapid amplification should facilitate analysis of the molecular mechanisms underlying these processes and their exploitation for a variety of therapeutic applications. View PublicationCatalog #: Product Name: 04434 MethoCult™ H4434 Classic 05100 MyeloCult™ H5100 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04464 Starter Kit for MethoCult™ H4434 Classic 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04330 MethoCult™ H4330 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 05100 Product Name: MyeloCult™ H5100 Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Meydan N et al. ( 1996) Nature 379 6566 645--648Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.
Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage. Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation. Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias, attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth. Here we show that leukaemic cells from patients in relapse have constitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.Catalog #: Product Name: 72932 AG-490 Catalog #: 72932 Product Name: AG-490 Marth JD (MAY 1996) The Journal of clinical investigation 97 9 1999--2002Recent advances in gene mutagenesis by site-directed recombination.
Nagy A and Rossant J (MAR 1996) The Journal of clinical investigation 97 6 1360--5Targeted mutagenesis: analysis of phenotype without germ line transmission.
The available techniques for directed gene manipulation in the mouse are unprecedented in any multicellular organism and make the mouse an invaluable tool for unraveling all aspects of mammalian biology. To realize fully the potential of these genetic tools requires that phenotypic analysis be efficient, rapid, and complete. Genetic chimeras and mosaics, in which mutant cells are mixed with wild-type cells, can be used to augment standard analysis of intact mutant animals and alleviate the time required and the expense involved in generating and maintaining multiple strains of mutant mice.Items 685 to 696 of 6390 total
Shop ByFilter Results- Resource Type
-
- Reference 6390 items
- Area of Interest
-
- Angiogenic Cell Research 48 items
- Cancer 600 items
- Cell Line Development 137 items
- Chimerism 6 items
- Cord Blood Banking 23 items
- Drug Discovery and Toxicity Testing 176 items
- Endothelial Cell Biology 2 items
- Epithelial Cell Biology 156 items
- HIV 51 items
- HLA 7 items
- Immunology 733 items
- Infectious Diseases 1 item
- Neuroscience 486 items
- Stem Cell Biology 2484 items
- Transplantation Research 53 items
- Brand
-
- ALDECOUNT 7 items
- ALDEFLUOR 223 items
- AggreWell 55 items
- ArciTect 1 item
- BrainPhys 45 items
- ClonaCell 83 items
- CryoStor 65 items
- ES-Cult 74 items
- EasyPick 2 items
- EasySep 760 items
- EpiCult 12 items
- HepatiCult 1 item
- ImmunoCult 12 items
- IntestiCult 142 items
- Lymphoprep 25 items
- MammoCult 50 items
- MegaCult 35 items
- MesenCult 133 items
- MethoCult 481 items
- MyeloCult 75 items
- MyoCult 2 items
- NeuroCult 353 items
- NeuroFluor 1 item
- PancreaCult 3 items
- PneumaCult 78 items
- RSeT 6 items
- ReLeSR 1 item
- RoboSep 58 items
- RosetteSep 272 items
- STEMdiff 63 items
- STEMvision 9 items
- SepMate 42 items
- StemSpan 290 items
- TeSR 1581 items
- mFreSR 14 items
- Cell Type
-
- Airway Cells 40 items
- B Cells 134 items
- Brain Tumor Stem Cells 81 items
- Cancer Cells and Cell Lines 116 items
- Cardiomyocytes, PSC-Derived 8 items
- Dendritic Cells 59 items
- Dermal Cells 1 item
- Endothelial Cells 1 item
- Epithelial Cells 48 items
- Granulocytes and Subsets 61 items
- Hematopoietic Stem and Progenitor Cells 765 items
- Hepatic Cells 2 items
- Hybridomas 73 items
- Innate Lymphoid Cells 3 items
- Intestinal Cells 12 items
- Leukemia/Lymphoma Cells 8 items
- Mammary Cells 68 items
- Mesenchymal Stem and Progenitor Cells 132 items
- Monocytes 105 items
- Mononuclear Cells 32 items
- Myeloid Cells 99 items
- NK Cells 79 items
- Neural Cells, PSC-Derived 17 items
- Neural Stem and Progenitor Cells 376 items
- Neurons 134 items
- Plasma 3 items
- Pluripotent Stem Cells 1676 items
- Prostate Cells 7 items
- Renal Cells 2 items
- T Cells 178 items
- T Cells, CD4+ 84 items
- T Cells, CD8+ 48 items
- T Cells, Regulatory 18 items
Loading...Copyright © 2025 by ϳԹ. All rights reserved.